chronic inflammation
Merck breaks with Aqilion
Aqilion has completed the license and collaboration agreement with Merck for the joint development of the TAK1 program, targeting chronic inflammation....
Intervju
Aqilion's new program will be Best-in-Class
Aqilion develops treatments for diseases caused by chronic...
Intervju
Video
Expert Insights: Aqilion CEO on closing deal
At the BioStock Investor Meeting, Aqilion CEO Sarah...
Intervju
Video
Aqilion reaches licensing agreement with Merck
Aqilion focuses on developing new treatments for...
Intervju
Video